Protocols
21 protocol(s) meet the specified criteria
Disease Site: Esophagus
Protocol No.TitleStatus
09-0918Genetic and Environmental Determinants of Barrett Esophagus and Esophageal AdenocarcinomaOpen
12-040-EClinical Registry of Dental Outcomes in Head and Neck Cancer Patients (ORARAD) Open
20120139 A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials Open
201404139Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable SCCHNOpen
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid TumorsOpen
B8011001A Phase 1, Open-Label, Dose Escalation and Expansion Study of PF-06801591 in Patients with Locally Advanced or Metastatic Melanoma, Squamous Cell Head and Neck Cancer, Ovarian Cancer, Sarcoma, or Relapsed or Refractory Classic Hodgkin Lymphoma or Other Solid TumorsOpen
D6410C00001A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects with Solid Tumors or CTCL and in Combination with Durvalumab and Palliative Radiation in Subjects with Solid TumorsOpen
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
LCCC1330A Phase II study of carboplatin, paclitaxel and cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neckOpen
LCCC1413De-intensification of Radiation and Chemotherapy for Favorable-Risk HPV-related Oropharyngeal Squamous Cell CarcinomaOpen
LCCC1430Phase Ib trial of Dose-escalating AZD1775 in Combination with Concurrent Radiation and Cisplatin for Intermediate and High Risk Head and Neck Squamous Cell Carcinoma (HNSCC)Open
LCCC1509Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) not Eligible for Cisplatin TherapyOpen
LCCC1513UNC Barrett's Esophagus and Esophageal Cancer Biorepository (BEECAB)Open
LCCC1527Evaluation of the Chemotherapy Toxicity Risk Score for Treatment Decision in Elderly Patients with Advanced Solid CancerOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1601Symptom management needs of patients treated for head and neck cancerOpen
LCCC1623Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer careOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
MM-398-01-01-02A Phase 1 Study in Patients Treated with MM-398 (Nanoliposomal Irinotecan, nal-IRI,) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentOpen
TRT-001A Multi-center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA Followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard TherapyOpen